Drug Information

Drug General Information
Drug ID
D0XF8W
Former ID
DAP000660
Drug Name
Pyrazinamide
Synonyms
Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; PZA; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-Pyrazinecarboxamide; 2-carbamyl pyrazine
Drug Type
Small molecular drug
Indication Mycobacterium tuberculosis infection [ICD10:A15-A19] Approved [536472], [542307], [551871]
Therapeutic Class
Antitubercular Agents
Formula
C5H5N3O
InChI
InChI=1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
InChIKey
IPEHBUMCGVEMRF-UHFFFAOYSA-N
CAS Number
CAS 98-96-4
PubChem Compound ID
1046
PubChem Substance ID
3115, 5057, 78938, 602930, 866420, 3135875, 7437580, 7847212, 7980439, 8002616, 8139959, 8149510, 10321757, 10539072, 11111657, 11111658, 11335416, 11360655, 11363796, 11366358, 11368920, 11371892, 11374989, 11377082, 11461627, 11466542, 11467662, 11485105, 11486124, 11489121, 11490861, 11493000, 11494716, 15119868, 16957225, 17389747, 17405569, 24278648, 24439399, 24887930, 25623302, 26611902, 26679227, 26697102, 26747228, 26747229, 26752748, 39214717, 46507478, 47810638
ChEBI ID
ChEBI:45285
SuperDrug ATC ID
J04AK01
SuperDrug CAS ID
cas=000098964
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) Enoyl-[acyl-carrier-protein] reductase [NADH] Target Info Inhibitor [535045]
References
Ref 536472Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
Ref 542307(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7287).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535045Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.